Articles tagged with Myelin Sheath
Researchers at Upstate Medical University identified a crucial mechanism for determining myelin length, which varies throughout the nervous system and influences nerve signal speed. The findings, published in PLOS Biology, provide new insight into how the brain and spinal cord organize nervous system wiring.
A new drug patch is being developed to promote the repair of damaged myelin sheaths in multiple sclerosis patients. The patch, which delivers a low dose of theophylline, is being tested in a Phase I clinical trial for its safety and tolerability.
Researchers found that tumors can damage peripheral nerves before chemotherapy begins, leading to potential nerve damage and chronic pain. The study challenges the conventional thought that peripheral neuropathy is mostly due to chemotherapy treatment.
Researchers discovered that damaged myelin generates abnormal rhythms in the sleeping brain, linked to disruptions in brain circuit stability. This finding may help design non-invasive approaches to repair myelin during sleep, improving sleep quality in patients with MS and Alzheimer's disease.
Researchers at CUNY ASRC have uncovered a metabolic switch that influences the formation of myelinating cells, helping shape brain development. The study reveals that glucose levels act as a signal directing behavior during development and can be harnessed to protect myelin in the developing brain and promote repair in disease states.
A genetic mutation found in high-altitude animals may help regenerate myelin sheath and repair nerve damage in conditions like MS and cerebral paralysis. The mutation increases production of a metabolite that promotes myelin production and maturation.
Researchers found that certain types of CD8+ killer T cells are more abundant in people with MS and target the EBV virus, indicating the virus may trigger an immune response leading to progressive neurological damage. The study suggests that interfering with EBV could have a significant impact on other autoimmune diseases.
A randomized controlled trial found that lipoic acid had a small beneficial effect on slowing brain atrophy in people with progressive multiple sclerosis. However, it did not improve walking speed as the primary clinical outcome. The study suggests that lipoic acid may be worth further investigation for its potential benefits.
CEMIP is associated with the breakdown of myelin, a protective sheath around nerve cells. Elevated levels of the enzyme inhibit myelin regeneration in people with multiple sclerosis. Researchers hope targeting CEMIP may promote central nervous system repair and slow disease progression.
Scientists analyzed thousands of proteins in blood samples to understand when multiple sclerosis attacks the myelin sheath and nerve fibers. Researchers identified a protein called IL-3, which plays a key role in this early phase of damage.
Scientists have identified two compounds, K102 and K110, that could promote remyelination and modulate immune function in multiple sclerosis. These compounds showed promising results in mouse models and human cells, suggesting potential for treating MS and possibly other neurological diseases.
A study by UC Riverside researchers identifies a strong connection between demyelination and seizure activity in multiple sclerosis. The findings suggest targeted treatments could address the root cause of seizures without suppressing overall brain activity.
A new five-year NSF-funded study will investigate the role of dopamine in regulating changes to myelin caused by social isolation. The research aims to explore novel mechanisms that drive the breakdown of myelin, a fatty coating around nerve fibers in the brain.
Researchers found that cancer cells break down nerve protective covers, triggering chronic inflammation and immune exhaustion, making treatment resistant. Targeting the nerve injury pathway can reverse this resistance and improve treatment response.
Laminin-411 protein and its derived peptide A4G47 exhibit pro-myelinating activity in oligodendrocytes, promoting myelin sheath formation. This discovery advances understanding of myelin sheath formation and potential applications for treating demyelinating diseases.
A rodent study found hnRNP A1 regulates myelin production and maintains its integrity, suggesting an impact on neurodegenerative diseases like schizophrenia. The findings provide new insights into the disease's molecular basis and potential treatments.
A study found that marathon runners experience a decrease in brain myelin content, but it recovers fully two months later. Myelin acts as an energy reserve, and the study opens new insights into brain energy metabolism.
A research group has uncovered a potential mechanism linking maternal inflammation to delayed neurodevelopment in infants. CD11c-positive microglia, crucial for myelination, play a key role in this process.
Researchers identified a potential new treatment for aggressive sarcoma arising in nerves, using a pre-clinical platform that combines inhibitors targeting specific mutations. The triple combination of MEKi-BETi-CDKi showed promising results in shrinking tumors and even eliminating some cases, offering hope for improved treatment options.
A new study from the University of Southern Denmark reveals that the brain's self-healing abilities are hindered by inflammation after a stroke. The researchers mapped specific cells that play a central role in rebuilding myelin, but found gender differences in how men and women respond to injuries.
The InteReg project aims to create interactive biomaterials that instruct cells to regenerate after brain or spinal cord injuries, potentially treating MS and other neurological disorders. The project, funded by the Carl Zeiss Foundation, brings together experts in biology, chemistry, medicine, and polymer research.
Research by Prof. Falkai suggests promising new directions in schizophrenia treatment through brain plasticity and myelin regeneration. His work challenges traditional views of the disorder and opens new therapeutic possibilities, particularly when combining aerobic exercise with a repurposed drug.
Scientists have discovered a natural compound called sulfuretin that can halt the progression of certain forms of cancer and demyelinating conditions like multiple sclerosis. The study found that sulfuretin blocks the activity of an enzyme involved in these diseases, suggesting its potential as a treatment.
Researchers explore immune activation and tumor-promoting transcription factor FOXM1's role in CDK4/6-MEK resistance. They suggest targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 as future treatment options for MPNST patients.
Researchers at the Plasticity and Remodeling of Neural Circuits laboratory aim to stimulate myelin plasticity to regenerate affected nerve fibers in MS patients. The team will explore gene therapy, pharmacological approaches, and rehabilitation strategies to enhance myelin repair.
Glial cells play a significant role in Alzheimer's disease, producing amyloid beta and contributing to plaque formation. Researchers discovered that knocking out BACE1 enzyme in oligodendrocytes reduced plaque formation by 30%, opening up new avenues for therapies.
Researchers have developed a new therapy called PIPE-307 that targets an elusive receptor on certain cells in the brain, prompting them to mature into myelin-producing oligodendrocytes. This could potentially reverse damage caused by multiple sclerosis, leading to improved movement, balance, and vision.
Researchers from Jilin University provide a comprehensive overview of brain injury biomarkers, including neuron-specific enolase, ubiquitin C-terminal hydrolase-L1, and neurofilament proteins. These biomarkers can help identify brain injuries and predict disease progression.
Researchers discovered that PMP22 duplication disrupts lipid metabolism and plasma membrane organization in developing Schwann cells, leading to myelin degradation and nerve damage. Targeting dysregulated lipid pathways may reverse some detrimental effects of CMT1A.
Researchers have discovered a small molecule compound called ESI1 that can regenerate vital myelin coatings, potentially treating multiple sclerosis and age-related cognitive deficits. The treatment promotes healing by clearing a roadblock in the repair process, allowing oligodendrocytes to produce myelin sheaths.
Researchers develop gene therapy to delay progression of metachromatic leukodystrophy by correcting enzyme deficiency and reducing neuroinflammation. Successful treatment has been demonstrated in mice, paving the way for potential human clinical trials.
Researchers discovered that mature oligodendrocytes, critical for brain function, can survive for up to 45 days after a fatal trauma, defying the classical programmed cell-death pathway. This finding opens new avenues for understanding and potentially preventing damage caused by aging and neurodegenerative diseases.
Researchers found that ageing reduces the ability of regulatory T cells to enhance myelin regeneration, which can have profound consequences for neurological functions. The study suggests that the loss of function may be reversible, and two new molecules, ITGA2 and MCAM, have been identified as potential therapeutic targets.
A recent study by researchers at LMU Munich discovered that neural networks adapt to sensory stimulation on an individual nerve fiber basis, rather than transferring improvements to neighboring fibers. This finding suggests that varied sensory experience throughout life is essential for maintaining cognitive fitness.
Researchers found that ancient retroviruses are essential for myelin production in mammals, amphibians, and fish. The gene sequence RetroMyelin is likely a result of ancient viral infection, and its presence is necessary for myelination to occur.
Researchers at ETH Zurich have developed a new magnetic resonance imaging (MRI) procedure that maps the condition of myelin sheaths in the central nervous system more accurately. This breakthrough technology has the potential to facilitate early MS diagnosis and monitoring, as well as the development of new drugs for the disease.
Researchers have uncovered the molecular and ultrastructural features of BCAS1+ cells in diffuse gliomas, highlighting their proliferative capacity and distribution. The study provides a comprehensive characterization of the BCAS1+ cell population within diffuse gliomas, shedding light on its role in tumor malignancy.
Researchers discovered that a little-understood synapse in the brain plays a pivotal role in producing myelin, the protective sheath around nerve cells. This finding could lead to new therapies for multiple sclerosis, neurodegenerative conditions and brain cancer.
Researchers at Tokyo Medical and Dental University develop a genome-editing technique that decreases PMP22 protein levels in patient cells, potentially reversing CMT-related changes. The study aims to improve myelination abilities and reduce symptoms in patients with CMT type 1A.
A small molecule drug compound has shown promise in treating multiple sclerosis by targeting the glutamate system, reducing MS-like symptoms and repairing damaged myelin. The results come from a CAMH-led pre-clinical study published in Science Advances.
Researchers found an inverse relationship between axon loss and demyelination, suggesting that 'bad' myelin can be more damaging than its absence. This study identifies potential therapeutic targets for diseases associated with myelin defects and inflammation in the nervous system.
A study published by UCI researchers found that N-acetylglucosamine reduced multiple inflammation and neurodegeneration markers in patients with Multiple Sclerosis. The dietary supplement also improved neurological function in 30% of patients, suggesting a potential new treatment for the condition.
Researchers found that ferroptosis, a form of cell death caused by iron buildup, destroys microglia cells in the brain's immune response, contributing to cognitive decline. The study's findings may lead to the development of compounds targeting microglial degeneration, offering new hope for Alzheimer's and vascular dementia treatments.
Researchers have developed a technique to measure the effectiveness of clemastine in repairing myelin, allowing for future therapies to be assessed. Patients with MS treated with clemastine experienced modest increases in myelin water, indicating myelin repair.
A team of neurobiologists has found that fruit flies possess glial sheath structures similar to those in vertebrates, enabling rapid transmission of nerve impulses. The study reveals the evolution of these structures and their role in supporting neuronal function.
Defective myelin promotes disease-related changes in Alzheimer's by accelerating amyloid plaque deposition and overwhelming immune cells. Slowing down age-related myelin damage could lead to new therapies and prevent or slow down the disease.
Researchers developed a method to 'tip the balance' of immune cells from bad to good, reversing MS-like symptoms in 100% of mice and achieving full recovery in 38%. The therapy uses biodegradable microparticles to deliver three key therapeutic agents, including rapamycin and a myelin peptide.
A team of researchers found that a small population of nerve cells exists in everyone that could be coaxed to regrow, potentially restoring sight and movement. The discovery provides new insights into how axons grow and could lead to effective therapies for blindness, paralysis, and other disorders caused by nerve damage.
A study found structural abnormalities in MS patients' white matter even before inflammation begins. Researchers discovered that myelin was less tightly wrapped around nerve fibers, disrupting signal transmission and leading to increased energy needs and oxidative stress.
Researchers at Duke-NUS Medical School have identified a special transporter protein that regulates the formation of myelin sheaths in the brain, which protect nerves from damage. The study suggests that omega-3 fatty acid lipids play a crucial role in directing oligodendrocyte development, a process critical for brain myelination.
A cell therapy using myeloid cells bound to drug delivery microparticles reduces disease burden in a preclinical multiple sclerosis model. The therapy partially reverses hind limb paralysis and improves motor functions.
Researchers at UC Davis discovered how oligodendrocyte-lineage cells transfer cell material to neurons in the mouse brain, providing a new mechanism for understanding brain maturation and finding treatments for neurological conditions. This discovery opens new possibilities for treating neurodegenerative diseases like Alzheimer's and P...
A Rutgers study found that criteria used to diagnose multiple sclerosis in adults may not be sufficient for pediatric patients, who often go undetected in early stages. The study suggests that diagnostic tools used for adults may need to be re-evaluated for children with abnormal MRI findings.
A University of Alberta researcher has found that fractalkine triggers the repair of brain damage caused by multiple sclerosis, leading to increased production of vital brain cells. This discovery could potentially halt or reverse MS symptoms by replacing damaged cells with new ones.
Researchers have discovered that propionate reduces cell death in nerve cells and promotes regeneration in the peripheral nervous system. The study found that propionate targets specific receptors and affects DNA reading to produce protective enzymes and proteins.
Researchers at Aarhus University are developing a novel treatment for multiple sclerosis by spinning artificial nerve fibers using electro-spun fibres. The goal is to restore nerve impulses quickly, as the myelin sheath deteriorates with age.
Researchers found that myelin accumulates axonal mitochondria in PV cells, supporting their high energy demand due to intense activity. This differs from other cell types where mitochondria are evenly distributed or more abundant when myelin is reduced.
Researchers identified Spns2, an S1P transporter, as a novel drug target for Multiple Sclerosis treatment. Targeting this protein may improve safety profiles and reduce side effects associated with current therapies.
CU Anschutz researchers found changes in myelination during learning, altering neuronal communication speed. These changes could lead to better treatment for neurological injuries and disorders like multiple sclerosis.
Researchers identified a kinase molecule that directs microglia activity, potentially treating neurodegenerative diseases like Alzheimer's and MS. The molecule, called spleen tyrosine kinase, targets plaque buildup and debris accumulation in the brain.